Increased collagen, per se, may not affect left ventricular function in spontaneously hypertensive rats

Dinko Susic1, Edward D Frohlich

  • 1Hypertension Research Laboratory, Division of Research, Ochsner Clinic Foundation, New Orleans, LA.

Ochsner Journal
|October 1, 2011
PubMed

Insights

Moderate left ventricular fibrosis, induced by inhibiting matrix metalloproteinases, did not impair cardiac function in hypertensive rats. This suggests other collagen changes, not just accumulation, cause fibrosis-related cardiac dysfunction.

Area of Science:

  • Cardiovascular Research
  • Cardiac Fibrosis
  • Matrix Metalloproteinase Inhibition

Background:

  • Left ventricular fibrosis is a key factor in cardiac dysfunction.
  • Quantifying fibrosis's role is challenging due to concurrent myocyte and vascular changes.
  • Matrix metalloproteinase (MMP) inhibitors can induce collagen accumulation.

Purpose of the Study:

  • To investigate the specific role of myocardial fibrosis in cardiac dysfunction.
  • To determine if doxycycline-induced collagen accumulation affects cardiac function.
  • To isolate the impact of fibrosis from other pathological changes.

Main Methods:

  • Adult male spontaneously hypertensive rats were used.
  • One group received doxycycline (MMP inhibitor) for 6 months; a control group received no treatment.
  • Cardiac function, arterial pressure, aortic stiffness, and myocardial collagen were assessed.

Main Results:

  • Doxycycline treatment significantly increased ventricular collagen concentration.
  • Arterial pressure and aortic stiffness remained unchanged.
  • Left ventricular function, including dP/dt and diastolic time constant, was unaffected.

Conclusions:

  • Moderate collagen accumulation alone does not adversely affect cardiovascular function.
  • Other collagen modifications, such as advanced glycation end-products, may drive fibrosis-related dysfunction.
  • This study helps differentiate the direct impact of fibrosis on cardiac health.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...